This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Angiex, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Manish S. Hudlikar: Innovator in Antibody-Drug Conjugates
Introduction
Manish S. Hudlikar is a prominent inventor based in Brookline, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates (ADCs). His innovative work focuses on enhancing the efficacy of cancer treatments through targeted therapies.
Latest Patents
Manish holds a patent for "Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same." This patent describes ADCs that include anti-TM4SF1 antibodies and their antigen-binding fragments. The methods of using these ADCs are also detailed, showcasing their potential in therapeutic applications.
Career Highlights
Manish is currently associated with Angiex, Inc., a company dedicated to advancing cancer therapies. His role at Angiex allows him to leverage his expertise in antibody-drug conjugates to contribute to innovative treatment solutions.
Collaborations
He collaborates with notable colleagues, including Paul A. Jaminet and Shou-Ching S. Jaminet, who share his commitment to advancing medical science through innovative research.
Conclusion
Manish S. Hudlikar's work in the field of antibody-drug conjugates exemplifies the impact of innovation in biotechnology. His contributions are paving the way for more effective cancer treatments, highlighting the importance of targeted therapies in modern medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile